Waseem Fathalla1, Elamin Ahmed. 1. Division of Pediatric Neurology, Pediatric Institute, Sheikh Khalifa Medical City, 51900, Abu Dhabi, UAE, wfathalla@yahoo.com.
Abstract
OBJECTIVE: We aim to present our experience with infantile Pompe disease with focus on the impact of availability of treatment on awareness, diagnosis, and management of such patients. METHOD: Case - review study of patients diagnosed with infantile Pompe disease and literature search. RESULTS: We identified five cases of infantile Pompe disease. The first was diagnosed by muscle biopsy; all others were diagnosed by enzyme assay on peripheral blood lymphocytes or dried blood spot. There was no determination of the CRIM status on these patients. Two have died at a much later age than the reported median age of death for untreated cases. One died very early at 2 months of age with severe cardiomyopathy and had received only one dose of enzyme replacement therapy (ERT). The remaining two surviving patients are siblings: the younger was diagnosed by prenatal ultrasound screening and started on ERT at 24 h of age; she is the youngest treated patient in our case series. CONCLUSION: The natural history of infantile Pompe disease is changing, so are the challenges of managing these infants in the post- ERT era. Currently, increased awareness and early access to therapy provide the best outcomes and incur the least shift of burden from mortality to morbidity. Disclosure: Authors have received travel support to attend scientific symposiums by Genzyme. WF has also received consulting fees for speaking in a scientific symposium by Genzyme.
OBJECTIVE: We aim to present our experience with infantile Pompe disease with focus on the impact of availability of treatment on awareness, diagnosis, and management of such patients. METHOD: Case - review study of patients diagnosed with infantile Pompe disease and literature search. RESULTS: We identified five cases of infantile Pompe disease. The first was diagnosed by muscle biopsy; all others were diagnosed by enzyme assay on peripheral blood lymphocytes or dried blood spot. There was no determination of the CRIM status on these patients. Two have died at a much later age than the reported median age of death for untreated cases. One died very early at 2 months of age with severe cardiomyopathy and had received only one dose of enzyme replacement therapy (ERT). The remaining two surviving patients are siblings: the younger was diagnosed by prenatal ultrasound screening and started on ERT at 24 h of age; she is the youngest treated patient in our case series. CONCLUSION: The natural history of infantile Pompe disease is changing, so are the challenges of managing these infants in the post- ERT era. Currently, increased awareness and early access to therapy provide the best outcomes and incur the least shift of burden from mortality to morbidity. Disclosure: Authors have received travel support to attend scientific symposiums by Genzyme. WF has also received consulting fees for speaking in a scientific symposium by Genzyme.
Authors: Wendy E Smith; Jennifer A Sullivan-Saarela; Jennifer S Li; Gerald F Cox; Deyanira Corzo; Yuan-Tsong Chen; Priya S Kishnani Journal: Am J Med Genet A Date: 2007-11-01 Impact factor: 2.802
Authors: Luke Y-J Wang; Allison K Ross; Jennifer S Li; Stephanie M Dearmey; Joanne F Mackey; Maryalice Worden; Deyanira Corzo; Claire Morgan; Priya S Kishnani Journal: Paediatr Anaesth Date: 2007-08 Impact factor: 2.556
Authors: Priya S Kishnani; Deya Corzo; Nancy D Leslie; Daniel Gruskin; Ans Van der Ploeg; John P Clancy; Rosella Parini; Gilles Morin; Michael Beck; Mislen S Bauer; Mikael Jokic; Chen-En Tsai; Brian W H Tsai; Claire Morgan; Tara O'Meara; Susan Richards; Elisa C Tsao; Hanna Mandel Journal: Pediatr Res Date: 2009-09 Impact factor: 3.756
Authors: Tim A Kanters; Marloes L C Hagemans; Nadine A M E van der Beek; Frans F H Rutten; Ans T van der Ploeg; Leona Hakkaart Journal: J Inherit Metab Dis Date: 2011-04-16 Impact factor: 4.982